Internal Reference Number: FOI_6469
Date Request Received: 10/02/2022 00:00:00
Date Request Replied To: 01/03/2022 00:00:00
This response was sent via: By Email
Request Summary: Treatment of dermatological conditions
Request Category: Campaigning organisation
| Question Number 1: How many patients were treated in January 2022 (or latest available month) by the dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Bimekizumab (Bimzelx) • Brodalumab (Kyntheum) • Dupilumab (Dupixent) • Ixekizumab (Taltz) • Risankizumab (Skyrizi) • Guselkumab (Tremfya) • Secukinumab (Cosentyx) • Tildrakizumab (Ilumetri) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq) • Ustekinumab (Stelara) | |
| Answer To Question 1: abrocitinib 0 baricitinib 0 bimekizumab 0 brodalumab 9 dupilumab 13 ixekizumab 4 risankizumab 0 guselkumab 10 secukinumab 5 tildrakizumab 3 tralokinumab 0 upadacitinib 0 ustekinumab 15 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
